Here's Why Solid Biosciences Stock Got Hammered Today
Shares of Solid Biosciences (NASDAQ: SLDB) are getting hammered today, down by 14% as of 11:54 a.m. EST, after the company released data from two Duchenne muscular dystrophy patients treated with the higher dose of its gene therapy SGT-001.
Unfortunately, there are safety issues with the higher dose, and the results for the two patients that didn't have severe adverse events don't look as promising as results from Sarepta Therapeutics' competing gene therapy.
Image source: Getty Images.
Source Fool.com
